ChiCTR2000028948 版本V1.4 版本创建时间2020/02/06 19:59:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000028948 

最近更新日期:

Date of Last Refreshed on:

2020-01-26 10:13:05 

注册时间:

Date of Registration:

2020-01-08 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于病毒载量预测高危型人乳头瘤病毒感染自然结局的研究

Public title:

A study for prediction of high-risk human papillomavirus infection natural outcome based on viral load

注册题目简写:

English Acronym:

研究课题的正式科学名称:

同步HPV分型及标准化定量预测高危型HPV感染转归的阈值研究

Scientific title:

A study for prediction of high-risk human papillomavirus infection natural outcome based on the synchronous HPV genotyping and quantification assay

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龙馨 

研究负责人:

龙馨 

Applicant:

Long Xin 

Study leader:

Long Xin 

申请注册联系人电话:

Applicant telephone:

+86 13608385160

研究负责人电话:

Study leader's
telephone:

+86 13608385160

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

4261749@qq.com

研究负责人电子邮件:

Study leader's E-mail:

4261749@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝北区龙山路120号

研究负责人通讯地址:

重庆市渝北区龙山路120号

Applicant address:

120 Longshan Road, Yubei District, Chongqing, China

Study leader's address:

120 Longshan Road, Yubei District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市妇幼保健院

Applicant's institution:

Chongqing Health Center for Woman and Children

研究负责人所在单位:

重庆市妇幼保健院

Affiliation of the Leader:

Chongqing Health Center for Woman and Children

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

L2017055

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆市妇幼保健院医学伦理委员会

Name of the ethic committee:

The medical ethics committee of Chongqing Health Center for Woman and Children

伦理委员会批准日期:

Date of approved by ethic committee:

2017-11-09 00:00:00

伦理委员会联系人:

贺凌云

Contact Name of the ethic committee:

15826126256

伦理委员会联系地址:

重庆市渝北区龙山路120号

Contact Address of the ethic committee:

120 Longshan Road, Yubei District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 023 63316835

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市妇幼保健院

Primary sponsor:

Chongqing Health Center for Woman and Children

研究实施负责(组长)单位地址:

重庆市渝北区龙山路120号

Primary sponsor's address:

120 Longshan Road, Yubei District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市妇幼保健院

具体地址:

重庆市渝北区龙山路120号

Institution
hospital:

Chongqing Health Center for Woman and Children

Address:

120 Longshan Road, Yubei District

经费或物资来源:

重庆市科学技术委员会

Source(s) of funding:

Chongqing Science and Technology Commission

研究疾病:

高危型人乳头瘤病毒感染  

Target disease:

high-risk human papillomavirus infection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探讨型别特异型人乳头瘤病毒感染的自然转归规律,确立HPV 载量预测高危型人乳头瘤病毒(HR-HPV)感染转归的最佳阈值。  

Objectives of Study:

Explore the natural outcome of type specific high-risk human papillomavirus (HR-HPV) infection based on viral load and determine the optimal cutoff of type-specific HR-HPV viral load for prediction of the infection natural outcome.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①居住在重庆地区的21岁~65岁有性生活的妇女;
②初次单一型别HR-HPV阳性;
③签署知情同意书。

Inclusion criteria

1. Aged 21-65 year old women living in Chongqing with sexual life;
2. women with single type HPV infection for the first time;
3. Subjects with follow-up conditions that volunteering to participate in it and have signed informed consent.

排除标准:

①曾患宫颈癌前病变及宫颈癌病史;
②免疫抑制患者或/和口服免疫抑制剂史;
③吸烟者;
④恶性肿瘤病史;
⑤妊娠或有妊娠计划;
⑥HPV感染药物干预。

Exclusion criteria:

1. history of cervical precancerous lesions and cervical cancer;
2. immunosuppressive patients;
3. smokers;
4, history of malignant tumors;
5. pregnancy or has pregnancy plan;
6. HPV infection drug intervention.

研究实施时间:

Study execute time:

From 2017-11-30 00:00:00 To 2020-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-11-30 00:00:00 To 2020-09-30 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

2000

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市妇幼保健院 

单位级别:

三级甲等 

Institution
hospital:

Chongqing Health Center for Woman and Children

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

HPV病毒载量

指标类型:

主要指标

Outcome:

HPV viral load

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

宫颈脱落细胞

组织:

Sample Name:

cervical exfoliated cells

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 21 years
最大 Max age 65 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

未使用随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

We don't use random methods

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

No

Blinding:

No

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

即时公开 ResMan,http://www.medresman. org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Real time access ResMan,http://www.medresman. org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan www.medresman.org

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan www.medresman.org

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-01-08 23:26:44